What guidance did Profound Medical's management provide for the next earnings period?

What is Profound Medical's gross profit margin?

Did Profound Medical beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Profound Medical year over year?

What factors drove the changes in Profound Medical's revenue and profit?

What were the key takeaways from Profound Medical's earnings call?

What is Profound Medical's latest dividend and current dividend yield?

What does Profound Medical do and what are its main business segments?

- **Revenue Surge**: Q3 2025 revenue up 87% YoY to $5.3M, driven by TULSA-PRO adoption and AI software launch.
- **Margin Expansion**: Gross margin hits 74.3%, with path to 70%+ as scale economies take hold.
- **BPH Breakthrough**: New AI software enables 60-90 minute procedures, targeting 10%+ of total cases in 2026.
- **Sonalleve Growth**: 10+ global sites treating uterine diseases, with trials for pancreatic cancer expanding addressable market.
- **Profitability Path**: 70-75% YoY growth, 200+ TULSA-PRO sites by 2026, and cash flow positivity as revenue scales.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $5.3M (87% YoY growth), with $4.1M recurring and $1.2M capital sales.
- Gross margin: 74.3% (vs. 63.1% in Q3 2024).
- Operating expenses: $12.8M (20% YoY increase due to R&D and commercial expansion).
- Net loss: $8M ($0.26/share) vs. $9.4M ($0.38/share) in Q3 2024.
- Cash balance: $24.8M, with plans to achieve cash flow positivity as revenue scales.

**【President’s Clinical Update】**
- **TULSA AI Volume Reduction Software Launch**: Full release at RSNA 2025, with pilot showing 60-90 minute procedures and surgeon satisfaction.
- **Kapton Trial Milestone**: All 160 patients treated, with 1-year safety and 3-year efficacy data to be presented at RSNA and SUO.
- **BPH Expansion**: Targeting 10%+ of total procedures in 2026, with TULSA days enabling multiple cases per day.

**【CCO Commercial Momentum】**
- 70 TULSA-PRO sites installed, with 93 systems in final sales pipeline stages (verify, negotiate, contract).
- **Reimbursement Progress**: Medicare payments ~$13,000/case, commercial payers up to $65,000/case post-appeal.
- **Partnerships**: 25-for-200 program driving early breakeven, with global deals in Saudi Arabia, Australia, and Japan.

**【CEO Strategic Vision】**
- **Trifecta Growth Plan**: 200 TULSA-PRO sites, 40+ installs/year, $85M+ annual revenue by 2026.
- **Sonalleve Expansion**: 10+ global sites treating uterine fibroids and adenomyosis, with trials for pancreatic cancer.
- **Profitability Path**: 70-75% YoY revenue growth, 70%+ gross margin, and path to profitability as scale economies kick in.

**【Q&A Highlights】**
- **Utilization Trend**: Q4 2025 procedures up 30%+ vs. Q3, driven by Medicare CPT-1 adoption and private payer wins.
- **Pipeline Conversion**: 50-65% of late-stage pipeline expected to close in 2025-2026, with 70+ sites by year-end.
- **Sonalleve Focus**: Expanding into body cavity oncology (liver, pancreas) with MR-guided focused ultrasound.

PROF

PROF fundamentals

You can ask Aime